(1.26%) 5 127.79 points
(1.18%) 38 676 points
(1.99%) 16 156 points
(-1.22%) $77.99
(5.65%) $2.15
(0.02%) $2 310.10
(-0.16%) $26.79
(0.37%) $966.20
(-0.35%) $0.929
(-1.07%) $10.87
(-0.11%) $0.797
(0.35%) $91.45
Live Chart Being Loaded With Signals
Chimerix, Inc., a biopharmaceutical company, develops medicines to enhance the lives of patients living with serious diseases. The company's approved product is TEMBEXA (brincidofovir), a lipid conjugate through inhibition of viral DNA synthesis that is developed as a medical countermeasure for smallpox...
Stats | |
---|---|
今日成交量 | 158 256 |
平均成交量 | 433 854 |
市值 | 85.01M |
EPS | $0 ( 2024-05-02 ) |
下一个收益日期 | ( $-0.220 ) 2024-06-20 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -1.020 |
ATR14 | $0.0100 (1.04%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-20 | Kozin Marc D | Buy | 100 000 | Stock Option (Right to Buy) |
2024-03-20 | Kozin Marc D | Buy | 0 | |
2024-02-14 | Andriole Michael T. | Sell | 1 744 | Common Stock |
2024-02-14 | Laspaluto Michelle | Sell | 1 940 | Common Stock |
2024-02-14 | Jakeman David | Sell | 2 660 | Common Stock |
INSIDER POWER |
---|
88.97 |
Last 99 transactions |
Buy: 5 160 750 | Sell: 1 392 397 |
音量 相关性
Chimerix Inc 相关性 - 货币/商品
Chimerix Inc 财务报表
Annual | 2023 |
营收: | $324 000 |
毛利润: | $323 000 (99.69 %) |
EPS: | $-0.930 |
FY | 2023 |
营收: | $324 000 |
毛利润: | $323 000 (99.69 %) |
EPS: | $-0.930 |
FY | 2022 |
营收: | $33.82M |
毛利润: | $33.38M (98.68 %) |
EPS: | $1.970 |
FY | 2021 |
营收: | $1.98M |
毛利润: | $0.00 (0.00 %) |
EPS: | $-2.01 |
Financial Reports:
No articles found.
Chimerix Inc
Chimerix, Inc., a biopharmaceutical company, develops medicines to enhance the lives of patients living with serious diseases. The company's approved product is TEMBEXA (brincidofovir), a lipid conjugate through inhibition of viral DNA synthesis that is developed as a medical countermeasure for smallpox. Its clinical stage development programs include ONC201 a program for treating tumors which harbor the H3 K27M mutation in recurrent diffuse midline glioma patients; ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist that demonstrated enhanced non-competitive DRD2 antagonism relative to ONC201, which is in Phase I clinical trials to treat solid tumors; ONC212, an imipridone agonist of the orphan G protein-coupled receptors (GPCR) tumor suppressor GPR132, as well as ClpP for solid tumors and hematological malignancies, including pancreatic cancer and leukemias; and dociparstat sodium (DSTAT), which inhibits the activities of key proteins implicated in the resistance of acute myeloid leukemia blasts and leukemic stem cells to chemotherapy. The company has license agreements with Biomedical Advanced Research and Development Authority for the development of brincidofovir for use in the treatment of smallpox; Cantex Pharmaceuticals, Inc. to develop and commercialize a glycosaminoglycan compound; and SymBio Pharmaceuticals to develop, manufacture, and commercialize BCV for various human indications. Chimerix, Inc. was incorporated in 2000 and is headquartered in Durham, North Carolina.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。